Skip to main content

Zimmer Biomet guidance

  • ZBH · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$103.95+2.51%Close 17 Nov 2026 · Market value $19.62B

In its results release of 4 Nov 2026 (Q3 FY2026), Zimmer Biomet gave 1 forecast in figures, among them EPS (adjusted) of $8.50 to $8.60 for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · AdjustedFY2026$8.50 to $8.60Adjusted Diluted EPS $8.50- $8.60

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS · AdjustedFY2026$8.50 to $8.60Raised 3 times—To come

ZBH in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.